Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of Cabazitaxel in HER2-negative metastatic breast cancer with unresectable brain metastases
2012-000542-35Phase 2Terminated
- Sponsor
- The Clatterbridge Cancer Centre NHS Foundation Trust
- Start
- Feb 2013
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabazitaxel in breast cancer, sponsored by The Clatterbridge Cancer Centre NHS Foundation Trust. Primary endpoints: Overall CNS response after 6 cycles and 18-week survival. Started Feb 2013; status: terminated.
02
Drugs
cabazitaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2012-000542-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000542-35.